Sign Out
Asthma: Vannair pMDI is indicated for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting β2-agonist (LABA)) is appropriate in adults and adolescents. This includes: patients who are symptomatic on inhaled corticosteroid therapy; patients who are established on regular long acting β2-agonist and inhaled corticosteroid therapy.
Chronic obstructive pulmonary disease (COPD): Vannair is indicated for the symptomatic treatment of moderate to severe COPD (FEV1 ≤50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. Vannair is not indicated for the initiation of bronchodilator therapy in COPD.
